trending Market Intelligence /marketintelligence/en/news-insights/trending/bGKMcql_uvnw1Qc4IguX3w2 content esgSubNav
In This List

US FDA grants breakthrough therapy designation to Juno's lymphoma drug

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


US FDA grants breakthrough therapy designation to Juno's lymphoma drug

The U.S. FDA granted Juno Therapeutics Inc. and partner Celgene Corp.'s investigational drug JCAR017 a breakthrough therapy designation for the treatment of patients with relapsed/refractory aggressive large B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and certain other lymphomas.

The European Medicines Agency's Committee for Medicinal Products for Human Use and Committee for Advanced Therapies granted JCAR017 access to the priority medicines scheme for relapsed/refractory diffuse large B-cell lymphoma. A study is expected to begin in 2017.

The drug is currently not approved in any country.